DSTA 4637S

Drug Profile

DSTA 4637S

Alternative Names: Anti-S. aureus TAC - Genentech; DSTA4637S; RG-7861

Latest Information Update: 10 Nov 2015

Price : $50

At a glance

  • Originator Genentech
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Staphylococcal infections

Most Recent Events

  • 01 Oct 2015 Phase-I clinical trials in Staphylococcal infections (In volunteers) in USA (IV) (NCT02596399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top